Globe Newswire (Thu, 23-Jul 3:09 AM ET)
Genenta-Backed Sphia High Tech Reports Fiscal Year 2025 Results
Globe Newswire (Wed, 22-Jul 4:00 AM ET)
Genenta’s Bold Shift: Strategic Transformation and Defense Sector Expansion Signal New Era for GNTA
Market Chameleon (Tue, 27-Jan 4:53 AM ET)
Market Chameleon (Fri, 24-Oct 5:52 AM ET)
Market Chameleon (Fri, 24-Oct 3:05 AM ET)
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
Genenta Science S.P.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol GNTA.
As of July 28, 2026, GNTA stock price was flat at $1.59 with 84,381 million shares trading.
GNTA has a beta of 0.42, meaning it tends to be less sensitive to market movements. GNTA has a correlation of 0.00 to the broad based SPY ETF.
GNTA has a market cap of $37.26 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GNTA traded as high as $10.00 and as low as $.55.
GNTA has underperformed the market in the last year with a return of -57.9%, while SPY returned +17.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GNTA shares. However, GNTA has outperformed the market in the last 3 month and 2 week periods, returning +115.5% and +20.5%, while SPY returned +3.9% and -1.1%, respectively. This indicates GNTA has been having a stronger performance recently.
GNTA support price is $1.49 and resistance is $1.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNTA shares will trade within this expected range on the day.
